Xufang Wang

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

Zhimei Liu, G. Di Lorenzo, C. Buonerba, 2011, Expert opinion on pharmacotherapy.

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Tae Min Kim, Ray Page, R. Motzer, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed.

Billy Amzal, Zhimei Liu, E. Calvo, 2015, Clinical therapeutics.

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Beth Devine, P. Metrakos, B. Devine, 2013, Experimental Hematology & Oncology.